This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
Mikon Biotechnology is a leading supplier of high-purity peptide APIs, including Semaglutide, Terzapitide, Retatrutide, and Cagrilintide. Backed by over 20 years of R&D expertise, we deliver cutting-edge peptide therapeutics for diabetes, obesity, NASH, and cardiovascular diseases.
Explore Our ProductsShenzhen Mikon Biotechnology Co., Ltd is a biotechnology innovation company based in the Wisdom Park, Guangming District, Shenzhen, China. Our mission is to serve the world through advanced peptide drug development and GMP-compliant manufacturing.
Our core team brings over two decades of experience in peptide research, development, and large-scale production. We specialize in next-generation peptide APIs targeting metabolic disorders, immune modulation, and chronic diseases.
As a trusted partner to pharmaceutical companies and research institutions globally, we are committed to quality, sustainability, and regulatory compliance.
In peptide R&D and GMP production
CAS: 910463-68-2
White Powder | API QC Purity
CAS: 2023788-19-2
White Powder | API QC Purity
CAS: 2381089-83-2
White Powder | API QC Purity
CAS: 1415456-99-3
White Powder | API QC Purity
CAS: 851199-59-2
White Powder | API QC Purity
CAS: 69440-99-9
White Powder | API QC Purity
CAS: 90779-69-4
White Powder | API QC Purity
CAS: 14636-12-5
White Powder | API QC Purity
CAS: 125564-84-7
White Powder | API QC Purity
CAS: 861640-76-2
White Powder | API QC Purity
Tailored peptide design and synthesis with high purity and scalability. From mg to kg scale, we support research and commercial needs.
Full-cycle R&D support including sequence optimization, stability testing, formulation, and preclinical evaluation.
Regulatory documentation, CMC support, and global registration strategy for peptide-based therapeutics.
With over 143 million diabetic patients in China (23% of global cases), and type II diabetes accounting for ~90%, our GLP-1 analogs like Semaglutide offer effective glycemic control and weight management.
Global obesity reached 1.211 billion in 2020. Our dual and triple agonists (Terzapitide, Retatrutide, Cagrilintide) are at the forefront of next-generation weight loss therapies.
With 1.76 billion people affected by non-alcoholic fatty liver disease globally, our metabolic peptides show promise in improving liver health and reducing steatosis.
The Chinese cardiovascular drug market exceeds 90 billion yuan annually. Semaglutide has demonstrated a 20% reduction in major cardiovascular events in clinical trials.
Characterized by reduced bone density and increased fracture risk, osteoporosis is effectively managed with anabolic agents like Teriparatide.
Affecting millions globally, chronic constipation is effectively treated with Linaclotide, a guanylate cyclase-C agonist that enhances intestinal fluid secretion.
For inquiries about our peptide APIs, custom services, or partnerships, please visit our official website to get in touch.
Visit Official WebsiteNotice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系support@fobcompany.info 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact support@fobcompany.info
如果您是其他域名合作 也请联系support@fobcompany.info